Efficacy of the New Neuraminidase Inhibitor CS-8958 against H5N1 Influenza Viruses

Currently, two neuraminidase (NA) inhibitors, oseltamivir and zanamivir, which must be administrated twice daily for 5 days for maximum therapeutic effect, are licensed for the treatment of influenza. However, oseltamivir-resistant mutants of seasonal H1N1 and highly pathogenic H5N1 avian influenza...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiso, Maki, Kubo, Shuku, Ozawa, Makoto, Le, Quynh Mai, Nidom, Chairul A., Yamashita, Makoto, Kawaoka, Yoshihiro
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829070/
https://www.ncbi.nlm.nih.gov/pubmed/20195462
http://dx.doi.org/10.1371/journal.ppat.1000786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829070/
https://www.ncbi.nlm.nih.gov/pubmed/20195462
http://dx.doi.org/10.1371/journal.ppat.1000786

Ejemplares similares